Log In

New? Register Here

Seattle Genetics Inc.

21823 - 30th Drive S.E.

  • Main Phone: (425) 527-4000
  • Fax Number: (425) 527-4001
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Endorsements: None Provided
  • Announcements: 0


Seattle Genetics, Inc. is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma (s ALCL), after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology.


Not provided at this time


Not provided at this time


There are no company announcements at this time.

Company's Strengths and Specialties

There is no information provided at this time.